Establishing the prevalence of common, clinically relevant
tissue-specific autoantibodies following SARS CoV-2 infection
Alex G. Richter1 , Adrian M.
Shields1, Abid Karim1, David
Birch1, Sian E. Faustini1, Lora
Steadman2, Kerensa Ward 1, Timothy
Plant1, Gary Reynolds2, Tonny
Veenith3, Adam F. Cunningham2, Mark
T. Drayson1, David C. Wraith2
Clinical Immunology Service, Institute for Immunology and Immunotherapy,
University of Birmingham, Birmingham, UK
Institute of Immunology and Immunotherapy, University of Birmingham, UK
Department of Critical Care Medicine, University Hospitals Birmingham
NHS Trust, Birmingham, UK
Key words: COVID-19, SARS-CoV-2, autoimmunity, autoantibodies, Long
COVID
Word count:
Number of figures: 2
Number of tables: 2
Supplementary data: 2 tables